PMID- 31312140
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: 
      Focus on Asian Populations.
PG  - 726
LID - 10.3389/fphar.2019.00726 [doi]
LID - 726
AB  - The interaction between programmed cell death protein 1 (PD-1) and its ligand 
      programmed death-ligand 1 (PD-L1) induces exhaustions of cytotoxic lymphocytes in 
      the tumor microenvironment, which facilitates tumor immune evasion. PD-1/PD-L1 
      blockade therapy, which prevents the receptors and ligands from binding to each 
      other, disrupts the T-cell exhaustion signaling, thereby increasing antitumor 
      immunity. Inspiringly, it has revolutionized the treatment of many different 
      types of cancers including non-small-cell lung carcinoma, melanoma, lymphoma, and 
      so on. However, with the intention of generating an antitumor immune response, 
      PD-1/PD-L1 blockade may also lead to a spectrum of side effects. The profile of 
      adverse events (AEs) of PD-1/PD-L1 blockade is not exactly the same with other 
      immune checkpoint blockades, such as blockade of cytotoxic 
      T-lymphocyte-associated protein 4. Although cutaneous, gastrointestinal, and 
      pulmonary systems are common victims, AEs of PD-1/PD-L1 blockade might occur in 
      any other organ system of the human body. These toxicities can be 
      life-threatening if not managed promptly, and proper treatment intervention is 
      imperative for optimal control and prevention of severe damage. Currently, 
      clinical practice for the management of AEs in PD-1/PD-L1 blockade remains 
      sporadic and variable. The majority of initial clinical trials were carried out 
      in Caucasians. The trials of multiple races usually included a small portion of 
      Asian participants, and results were calculated and interpreted for the entire 
      included subjects without any race-specific conclusions. Therefore, the 
      information on PD-1/PD-L1 blockade in Asians is far from systematic or 
      comprehensive. Recently, as the results of clinical trials of anti-PD-1/PD-L1 
      agents in Asian populations have been gradually released, we summarized current 
      evidence with a specific focus on the Asian population, hoping to outline 
      strategies and offer guidance on the management of AEs in cancer patients treated 
      with PD-1/PD-L1 blockade in the Asian world.
FAU - Yang, Jiqiao
AU  - Yang J
AD  - Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for 
      Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
AD  - Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - He, Xiujing
AU  - He X
AD  - Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for 
      Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Lv, Qing
AU  - Lv Q
AD  - Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
AD  - Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Jing, Jing
AU  - Jing J
AD  - Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Shi, Hubing
AU  - Shi H
AD  - Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for 
      Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, Chengdu, China.
AD  - Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190702
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6614522
OTO - NOTNLM
OT  - Asian
OT  - adverse event
OT  - cancer
OT  - immunotherapy
OT  - programmed cell death protein 1
OT  - programmed death-ligand 1
EDAT- 2019/07/18 06:00
MHDA- 2019/07/18 06:01
PMCR- 2019/07/02
CRDT- 2019/07/18 06:00
PHST- 2019/04/15 00:00 [received]
PHST- 2019/06/05 00:00 [accepted]
PHST- 2019/07/18 06:00 [entrez]
PHST- 2019/07/18 06:00 [pubmed]
PHST- 2019/07/18 06:01 [medline]
PHST- 2019/07/02 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00726 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Jul 2;10:726. doi: 10.3389/fphar.2019.00726. eCollection 
      2019.